Key result
Truncated abstract omits quantitative hemodynamic effects of dobutamine in chronic systolic heart failure exacerbations.
Why the study?
Does dobutamine improve hemodynamic effects in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol?
Observational (n=31)
No
Does dobutamine improve hemodynamic effects in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol?
Truncated abstract yields no hemodynamic data; leaves open dobutamine effects in carvedilol-treated decompensated systolic HF.
Although most patients in Europe with systolic heart failure (SHF) are treated with I(2)-blocking agents at doses significantly lower than the recommended dose, there is limited information available regarding the hemodynamic effects of dobutamine in this patient population. Therefore, a study was carried out in patients (n=31) admitted to the University Hospital, Larissa, Greece with an acute exacerbation of chronic SHF (25 men and 6 women, mean age 58 years, range 32 â 80 years, left ventricular (LV) ejection fraction
No takes yet. Share an insight, caveat, or question.
Triposkiadis et al. (2008) conducted an observational in Acute exacerbation of chronic systolic heart failure (n=31). Dobutamine was evaluated. The provided abstract is truncated and does not report the quantitative hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: